Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics.

By CARMEN PAUN 4/9/19, © POLITICO PRO Healthcare U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.

Duane Schulthess of Vital Transformation sits down for a one on one discussion with Luca Pani, the Director General of the Italian Medicines Agency, to discuss his new book "Sustainable Innovation: Medicines and the Challenges for the Future of our National Health Service". This 30 minute podcast recording [...]